2014
DOI: 10.1097/qai.0000000000000205
|View full text |Cite
|
Sign up to set email alerts
|

A 48-Week Study of Fat Molecular Alterations in HIV Naive Patients Starting Tenofovir/Emtricitabine With Lopinavir/Ritonavir or Efavirenz

Abstract: Starting TDF/FTC plus EFV was associated with an increased expression of genes encoding for inflammatory cytokines in SAT in naive patients. Therapy with TDF/FTC plus LPV/r or EFV was associated with an increase in subcutaneous fat mass.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
9
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 12 publications
(9 citation statements)
references
References 33 publications
0
9
0
Order By: Relevance
“…Moreover, gene expression studies of subcutaneous adipose tissue may help us to better understand the mechanisms behind body fat changes in HIV-infected patients who initiate ART. Antiretroviral-drug-induced gene expression changes have been detected in adipocytes, in vitro (15,16) and in vivo, in healthy volunteers (17) and in HIV-infected patients (18)(19)(20)(21). In this study, we aimed to compare the effects of efavirenz (EFV) and those of ritonavir-boosted lopinavir (LPV/r), combined with emtricitabine and tenofovir, on body fat changes to evaluate the in vivo influence of each regimen on human subcutaneous adipose tissue gene expression and, additionally, to assess whether these transcript changes may be correlated with fat changes.…”
mentioning
confidence: 99%
“…Moreover, gene expression studies of subcutaneous adipose tissue may help us to better understand the mechanisms behind body fat changes in HIV-infected patients who initiate ART. Antiretroviral-drug-induced gene expression changes have been detected in adipocytes, in vitro (15,16) and in vivo, in healthy volunteers (17) and in HIV-infected patients (18)(19)(20)(21). In this study, we aimed to compare the effects of efavirenz (EFV) and those of ritonavir-boosted lopinavir (LPV/r), combined with emtricitabine and tenofovir, on body fat changes to evaluate the in vivo influence of each regimen on human subcutaneous adipose tissue gene expression and, additionally, to assess whether these transcript changes may be correlated with fat changes.…”
mentioning
confidence: 99%
“…Among ART-treated persons with lipodystrophy, mtDNA is depleted in both VAT and SAT, metabolism and adipogenesis markers are decreased in SAT, and less pro-inflammatory gene expression occurs in VAT, potentially protecting it from depletion [62]. Finally, SAT pro-inflammatory cytokines increase more with efavirenz (vs lopinavir-ritonavir) in combination with tenofovir and emtricitabine [59]. …”
Section: Discussionmentioning
confidence: 99%
“…The specific tissue pharmacodynamics of each INsTI will most likely be different and thus may cause different effects, if any, on different cell types of the depot. Invasive procedures, such as adipose tissue biopsies, would be instrumental for that purpose [19].…”
Section: Testing the Hypothesismentioning
confidence: 99%